UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 21.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,689,376 shares of the medical technology company's stock after purchasing an additional 481,175 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.70% of Stryker worth $846,723,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of SYK. New Mexico Educational Retirement Board raised its stake in Stryker by 7.5% in the second quarter. New Mexico Educational Retirement Board now owns 17,109 shares of the medical technology company's stock valued at $5,387,000 after buying an additional 1,200 shares in the last quarter. Mufg Securities Americas Inc. lifted its holdings in Stryker by 9.0% during the 2nd quarter. Mufg Securities Americas Inc. now owns 10,392 shares of the medical technology company's stock worth $3,272,000 after buying an additional 862 shares during the last quarter. Van ECK Associates Corp boosted its position in shares of Stryker by 7.6% during the 2nd quarter. Van ECK Associates Corp now owns 22,011 shares of the medical technology company's stock worth $6,930,000 after acquiring an additional 1,555 shares in the last quarter. Ferguson Wellman Capital Management Inc. boosted its position in shares of Stryker by 1.2% during the 2nd quarter. Ferguson Wellman Capital Management Inc. now owns 186,935 shares of the medical technology company's stock worth $58,855,000 after acquiring an additional 2,180 shares in the last quarter. Finally, Roffman Miller Associates Inc. PA increased its holdings in shares of Stryker by 1.0% in the 2nd quarter. Roffman Miller Associates Inc. PA now owns 127,268 shares of the medical technology company's stock valued at $40,069,000 after acquiring an additional 1,246 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on SYK shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a report on Friday, July 31st. Barclays reduced their price objective on shares of Stryker from $469.00 to $394.00 and set an "overweight" rating for the company in a research report on Monday, May 4th. JPMorgan Chase & Co. lowered their target price on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Citizens Jmp dropped their target price on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a research report on Monday, August 3rd. Finally, Raymond James Financial set a $370.00 price target on shares of Stryker in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $386.28.
Check Out Our Latest Analysis on SYK
Stryker Stock Performance
Shares of SYK stock opened at $331.32 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock has a 50 day simple moving average of $329.10 and a 200-day simple moving average of $331.47. The company has a market cap of $127.08 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.
Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the business earned $3.13 earnings per share. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.
Stryker Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's payout ratio is presently 36.48%.
Insider Transactions at Stryker
In related news, Director Ronda E. Stryker sold 300,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Debra King sold 826 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 in the last ninety days. 4.60% of the stock is currently owned by company insiders.
About Stryker
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
See Also
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
